Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie's strong financial outlook is supported by an increase in 2025 guidance for both global sales and earnings per share, with management projecting neuroscience segment sales to reach approximately $10.7 billion and adjusted EPS to range between $12.09 and $12.29. The company's recent quarterly performance surpassed expectations, bolstered by robust contributions from key products in their immunology and oncology franchises, including Skyrizi and Rinvoq, while also benefiting from advancements in neuroscience with contributions from Vraylar and Botox Therapeutic. Additionally, AbbVie's strategic acquisitions of Cerevel and ImmunoGen, alongside its established portfolio from the Allergan acquisition, position the firm for sustained growth and resilience in an evolving pharmaceutical landscape.

Bears say

AbbVie's stock faces multiple downside risks, primarily stemming from disappointing commercial execution across key products such as Skyrizi, Rinvoq, and Botox, which could hinder revenue growth. Furthermore, the company's heavy reliance on Humira may result in greater than expected sales erosion due to increasing market share of launched biosimilars, compounded by pressure from competitors in oncology and limited market penetration in neuroscience. Additionally, macroeconomic challenges impacting consumer spending, particularly within the Aesthetics segment, and pipeline uncertainties further contribute to a negative outlook for AbbVie’s financial performance.

AbbVie (ABBV) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 18 analysts, AbbVie (ABBV) has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $251.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $251.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.